Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2021-10-21 Environmental & Social …
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
BAXTER ET BIOMÉRIEUX ANNONCENT LE MARQUAGE CE DU TEST NEPHROCLEAR™ CCL14 POUR PRÉDIRE L'INSUFFISANCE RÉNALE AIGUË SÉVÈRE PERSISTANTE
Environmental & Social Information Classification · 99% confidence The document is a press release, indicated by the header "POUR DIFFUSION IMMEDIATE" and the inclusion of contact information for both Press and Investors. The content announces a significant business development: Baxter and bioMérieux receiving the CE mark for the NEPHROCLEAR™ CCL14 test and their plans for commercialization. This type of announcement, detailing a new product approval, partnership update, or significant operational milestone, is typically classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it contained financial results. Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific financing event (CAP), and it is a formal announcement of a regulatory/product milestone, the most appropriate general category is Regulatory Filings (RNS). It is not a Call Transcript (CT), Investor Presentation (IP), or a specific shareholder/director action. Given the nature of the announcement (product approval/launch strategy), RNS is the best fit as a broad regulatory/corporate update.
2021-10-21 French
BAXTER AND BIOMÉRIEUX ANNOUNCE CE MARK FOR NEPHROCLEAR™ CCL14 TEST TO PREDICT PERSISTENT SEVERE ACUTE KIDNEY INJURY
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Baxter and bioMérieux have received CE marking for the NEPHROCLEAR™ CCL14 Test, which predicts persistent severe Acute Kidney Injury (AKI). It details the product, its intended use, clinical significance, and collaboration terms. This type of announcement, focusing on a new product approval/launch or significant clinical development, is typically classified as a general corporate announcement or regulatory update. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder action (DIV, DVA), the most appropriate category is the general regulatory/corporate announcement fallback, RNS, as it pertains to a regulatory milestone (CE Mark) and product launch information. It is not an RPA because it is a detailed announcement of a development, not just an announcement that a report is attached or published.
2021-10-21 English
bioMérieux – Third-Quarter 2021 Business Review
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Third-Quarter 2021 Business Review" and explicitly states it releases its "business review for the nine months ended September 30, 2021." It contains detailed financial tables for Q3 and the nine-month period, management commentary, and an outlook revision. This structure is characteristic of a comprehensive interim financial report, which aligns with the definition of an Interim / Quarterly Report (IR). It is not just an initial earnings release (ER) as it provides extensive detail, nor is it the full Annual Report (10-K). The presence of an investor presentation link and calendar suggests it is the primary release of the period's results. 9M 2021
2021-10-21 English
bioMérieux – Information financière du 3ème trimestre 2021
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Information financière du 3 ème trimestre 2021" and provides detailed financial figures, growth rates (organic and published), revenue breakdowns by application and region, and management commentary for the first nine months and the third quarter ending September 30, 2021. This structure, focusing on a period shorter than a full year (9 months/Q3), clearly identifies it as a comprehensive interim financial report. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not just a brief release (ER) because it contains extensive tables and detailed segment analysis, nor is it the full Annual Report (10-K). 9M 2021
2021-10-21 French
Septembre 2021 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it provides "Informations mensuelles relatives au nombre total de droits de vote et d'actions" (Monthly information relating to the total number of voting rights and shares) as required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This structure, detailing the total number of shares and voting rights as of a specific date (30/09/2021), is characteristic of a mandatory regulatory disclosure concerning share capital structure and voting power. While it is a regulatory filing, the specific content—monthly voting rights and share count—does not perfectly align with the defined codes like DIRS (Director's Dealing) or SHA (Share Issue/Capital Change). However, it is a specific regulatory disclosure that is not covered by the other specific codes. Given the options, 'RNS' (Regulatory Filings - general/miscellaneous) is the most appropriate fallback for a specific, non-standard regulatory disclosure that doesn't fit the primary categories like 10-K, ER, or DIV. It is not a report announcement (RPA) because it contains the actual data, not just an announcement of a report.
2021-10-08 French
A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities
Regulatory Filings Classification · 95% confidence The document is a press release dated September 13th, 2021, announcing the results of a survey conducted by bioMérieux and the UK Sepsis Trust regarding sepsis awareness in Europe. It details survey findings, quotes executives and charity leaders, and provides background information on the organizations involved. This type of announcement, which communicates specific, non-periodic operational or research findings to the public and investors, most closely aligns with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a slide deck. However, given the format (press release style) and the content focusing on survey results and organizational collaboration rather than core financial performance (10-K, IR, ER) or management changes (MANG), the most appropriate general category for a non-standard announcement is Regulatory Filings (RNS). It is not a formal financial report, earnings release, or AGM material.
2021-09-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.